dr. backes on financial toxicity considerations in ovarian cancer
Published 4 years ago • 278 plays • Length 1:37Download video MP4
Download video MP3
Similar videos
-
1:06
dr. backes discusses her experience with parp inhibitors in ovarian cancer
-
0:56
dr. backes on quality of life with parp inhibitors in ovarian cancer
-
1:01
dr. backes on the film trial in endometrial cancer
-
1:11
dr. backes discusses parp inhibitor combinations in ovarian cancer
-
1:18
dr. backes on treatment selection with parp inhibitors in ovarian cancer
-
57:42
ovarcoming financial toxicity in ovarian cancer
-
0:46
dr. chase on toxicities with niraparib in ovarian cancer
-
0:53
dr. backes on next steps for lenvatinib and weekly paclitaxel in endometrial cancer
-
1:56
parp inhibitor costs give patients with ovarian cancer financial toxicity
-
0:49
dr. crafton on considerations for secondary cytoreduction in ovarian cancer
-
0:56
dr. klebanoff on biosimilars reducing financial toxicity in breast cancer
-
1:24
dr. ledermann on response to rucaparib in recurrent ovarian cancer
-
53:19
financial toxicity
-
58:15
the cost of cure: financial toxicity in cancer care
-
1:19
meet floor backes, md—gynecologic oncologist at the osuccc—james
-
1:30
dr. penson on research with parp inhibitors in ovarian cancer
-
1:13:10
the state of ovarian cancer: exploring the landscape of systemic therapy
-
2:09
collaborative studies on breast cancer risk in brca mutation carriers
-
4:21
financial toxicity for cancer patients